BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Mar 10, 2008
 |  BioCentury  |  Emerging Company Profile

CG Therapeutics: Hormone neutralizer

While most cancer vaccines aim to stimulate the immune system to boost T cell production, CG Therapeutics Inc. believes that generating an antibody response will provide better efficacy against cancer targets.

CG is developing antibody-based immunotherapies, including vaccines, targeting human chorionic gonadotropin (hCG), a hormone that is a key to promoting the progression of solid tumors based on its angiogenic properties and ability to shield cells from the immune system.

"hCG is a powerful hormone that is needed by embryos and cancer cells," said President Max Lyon. "When produced by human embryos, it shields the embryo from the mother's immune system and stimulates the growth of blood vessels that nourish the fetus. However, when hCG or its variants are produced by cancer cells, they begin to promote the nourishment, growth and spread of cancer."

hCG and its variants, hyperglycosylated hCG and beta...

Read the full 715 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >